




Social-communication difficulties in children/adolescents




Social-communication difficulties in adults




Repetitive behaviors in children/adolescents




Repetitive behaviors in adults




Overall core symptoms in children/adolescents




Overall core symptoms in adults




Irritability in children/adolescents




Irritability in adults




ADHD symptoms in children/adolescents




ADHD symptoms in adults




Anxiety or depressive symptoms in children/adolescents



Anxiety or depressive symptoms in adults




Caregiver stress in children/adolescents




Caregiver stress in adults


Study	Experimental		Control		Standardised Mean Difference	SMD	95%-CI
	Total	Mean	SD	Total			
comparison = balovaptan_placebo							
Bolognani_2019	111	5.67	15.9720	72	5.20	15.1000	0.03 [-0.27; 0.33]
NCT03504917	106	4.80	15.0000	92	3.30	14.0000	0.10 [-0.18; 0.38]
Random effects model	217		164				0.07 [-0.13; 0.27]
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.73$							
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.73$							




Global functioning in children/adolescents



Global functioning in adults




Quality of life in children/adolescents




Quality of life in adults


Study	Experimental Total Mean	SD	Control Total Mean	SD	Standardised Mean Difference	SMD	95%-CI
comparison = oxytocin_placebo							
Anagnostou_2012	10	11.70	16.1521	9	-2.00	12.3000	0.90 [-0.05; 1.86]
Watanabe_2015	9	0.03	0.6139	9	-0.02	0.8982	0.06 [-0.86; 0.99]
Bernaerts_2020	22	1.77	8.0400	17	-1.35	6.7400	0.41 [-0.23; 1.05]
Random effects model	41			35			0.44 [-0.02; 0.90]
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.46$							
comparison = balovaptan_placebo							
Bolognani_2019	111	7.43	10.6585	72	3.90	13.0000	0.30 [0.00; 0.60]
NCT03504917	106	8.00	13.7000	92	6.00	11.6000	0.16 [-0.12; 0.44]
Random effects model	217			164			0.22 [0.02; 0.43]
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.48$							
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.60$							




Response in children/adolescents




Response in adults




Dropouts due to any reason in children/adolescents




Dropouts due to any reason in adults




Dropouts due to adverse events in children/adolescents



Dropouts due to adverse events in adults




Any adverse events in children/adolescents




0.01 0.1 1 10 100

Any adverse events in adults




Sedation in children/adolescents




0.01 0.1 1 10 100


Sedation in adults




Weight gain in children/adolescents



Weight gain in adults



Extrapyramidal symptoms in children/adolescents



There were no data for extrapyramidal symptoms in adults